Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 10;17(11):e0276639.
doi: 10.1371/journal.pone.0276639. eCollection 2022.

Determinants of hydroxyurea use among doctors, nurses and sickle cell disease patients in Nigeria

Hezekiah Alkali Isa  1   2 , Uche Nnebe-Agumadu  1   3 , Maxwell M Nwegbu  1   4 , Emmanuel C Okocha  5 , Reuben I Chianumba  1 , Biobele J Brown  6 , Samuel A Asala  7 , Emmanuel Peprah  8 , Obiageli E Nnodu  1   2
Affiliations

Determinants of hydroxyurea use among doctors, nurses and sickle cell disease patients in Nigeria

Hezekiah Alkali Isa et al. PLoS One. .

Abstract

Background: Hydroxyurea (HU) is an evidence-based therapy that is currently the most effective drug for sickle cell disease (SCD). HU is widely used in high-income countries with consequent reduction of morbidity and mortality. In Nigeria, HU is prescribed by physicians while nurses are mainly involved in counseling the patients to ensure adherence. The extent of utilization and the determinant factors have not been sufficiently evaluated in Nigeria.

Objective: To assess the frequency of use of HU and factors affecting utilization among healthcare providers, patients, and caregivers for SCD.

Methods: A questionnaire was administered online and in- person to assess the frequency of HU use and the factors that promote and limit its use. The data were analyzed by descriptive statistics using IBM SPSS software version 23 and the result was presented in frequency tables and percentages.

Result: A total of 137 physicians, 137 nurses, and 237 patients/caregivers responded to the survey. The rate of prescription of HU by doctors in the past 6 months was 64 (46.7%), 43 (31.4%) nurses provided counseling and 36 (15.6%) patients were on HU. Among doctors, adequate knowledge (91.3%), clinical benefits and safety (94.8%), and inclusion of HU in management guidelines (86.9%) were motivators for prescribing it while inadequate knowledge (60.9%) and unawareness of treatment guidelines (68.6%) constituted barriers. Among nurses, reduction of crisis (91.6%) and safety (64.8%) were the major motivators while barriers were high cost (79.1%) and intensive monitoring (63.1%) of HU treatment. Among the patients, the major motivator was the reduction of crises (80.3%) while poor knowledge (93.2%), high cost of the drug (92.2%) while monitoring (91.2%), non-availability (87.7%) and side effects (83.9%) were the major barriers for the utilization of HU.

Conclusion: HU prescription and utilization are still poor among healthcare providers and patients. Inadequate knowledge, non-availability and high cost of HU as well as unawareness of treatment guidelines constitute major barriers to prescription and utilization.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. CONSORT diagram for patient participants (237 respondents).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ernest B. The Sickle Cell Disease and Related Disorders. In: Williams Haematology. McGraw Hill Medical Publishing Division. New York.6th Ed; 2000: 581–606.
    1. Piel FB, Hay SI, Gupta S, Weatherall JD, Williams NT. Global burden of sickle cell anaemia in children under five, 2010–2050: modeling based on demographics, excess mortality, and interventions. PLoS Med 2013; 10:e1001484. - PMC - PubMed
    1. Nnodu OE, Sopekan A, Nnebe-Agumadu U, Ohiaeri Chinatu, Adeniran Adeyemi, Shedul Grace et al.. Implementing newborn screening for sickle cell disease as part of immunization programmes in Nigeria: a feasibility study. Lancet Haematol 2020; 7(7): e534–e40. - PMC - PubMed
    1. Nnodu OE, Oron AP, Sopekan A, Akaba GO, Piel FB, Chao DL. Child mortality from sickle cell disease in Nigeria: a model-estimated, population-level analysis of data from the 2018 Demographic and Health Survey. Lancet Haematol 2021; 8(10): e723–e31. doi: 10.1016/S2352-3026(21)00216-7 - DOI - PMC - PubMed
    1. Rai P, Ataga KI. Drug Therapies for the Management of Sickle Cell Disease [version 1; peer review: 2 approved]. F1000Research 2020, 9(F1000 Faculty Rev):592 (10.12688/f1000research.22433.1) - DOI - PMC - PubMed

Publication types